Cipla Colombia SAS Y/O Deposito UPS

Cipla Colombia SAS Y/O Deposito UPS is a Colombian pharmaceutical importer and distributor headquartered in Bogotá D.C., Colombia. Established on April 25, 2019, the company operates as a Sociedad por Acciones Simplificada (SAS), a simplified joint-stock company structure commonly used in Colombia. Its primary activity is the wholesale distribution of pharmaceutical products, including medicinal drugs, cosmetics, and toiletries.

The company serves as a key player in Colombia's pharmaceutical supply chain, sourcing a diverse range of finished pharmaceutical formulations from international suppliers. This strategic approach enables Cipla Colombia SAS Y/O Deposito UPS to meet the growing demand for various therapeutic products within the Colombian market.

Cipla Colombia SAS Y/O Deposito UPS operates a centralized distribution model from its headquarters in Bogotá D.C., Colombia. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Bogotá suggests a focus on efficient distribution throughout Colombia. The capital city's infrastructure likely facilitates streamlined logistics, enabling the company to serve a broad geographic area within the country.

In Colombia's pharmaceutical supply chain, Cipla Colombia SAS Y/O Deposito UPS functions primarily as a wholesaler and distributor. By importing finished pharmaceutical formulations from international suppliers, the company plays a crucial role in ensuring the availability of a wide array of medicinal products across the Colombian market. This position allows Cipla Colombia SAS Y/O Deposito UPS to bridge the gap between global pharmaceutical manufacturers and local healthcare providers, contributing to the overall accessibility of essential medicines in Colombia.

Cipla Colombia SAS Y/O Deposito UPS demonstrates a high degree of sourcing concentration, with 100% of its pharmaceutical imports originating from a single supplier: Cipla Limited of India. This exclusive sourcing strategy indicates a deep-rooted partnership, potentially offering benefits such as favorable pricing, consistent product quality, and reliable supply chain management. However, this single-source dependency also introduces risks, including vulnerability to supply disruptions, price fluctuations, and potential regulatory changes affecting the supplier. The stability of this relationship is crucial; any disruptions could significantly impact Cipla Colombia SAS Y/O Deposito UPS's ability to meet market demand.

The resilience of Cipla Colombia SAS Y/O Deposito UPS's supply chain is closely tied to its exclusive relationship with Cipla Limited. While this partnership may offer streamlined operations and consistent product quality, it also exposes the company to risks associated with single-source dependency. The absence of backup suppliers and limited formulation diversity could pose challenges in the event of supply chain disruptions. Additionally, reliance on a single supplier may limit the company's ability to adapt to changing market demands or regulatory requirements. Ensuring compliance with Colombian regulations and maintaining a robust logistics framework are essential to mitigate potential vulnerabilities in the supply chain.

Cipla Colombia SAS Y/O Deposito UPS's sourcing pattern, characterized by exclusive reliance on Cipla Limited, positions the company to benefit from strong supplier relationships and potential cost advantages. However, this strategy also necessitates careful risk management to address potential supply chain disruptions and market fluctuations. For Indian exporters seeking to become alternative suppliers, understanding the dynamics of this exclusive relationship is crucial. Offering complementary products, ensuring competitive pricing, and demonstrating reliability in supply chain operations could present viable opportunities to diversify Cipla Colombia SAS Y/O Deposito UPS's sourcing base.

In Colombia, the primary regulatory authority overseeing pharmaceutical imports is the National Institute for Food and Drug Surveillance (INVIMA). INVIMA is responsible for ensuring the safety, efficacy, and quality of health-related products entering the Colombian market. The regulatory framework governing pharmaceutical imports includes Decree 677 of 1995, which outlines the sanitary registration requirements for drugs and biological products. This decree mandates that all pharmaceutical products imported into Colombia must obtain sanitary registration from INVIMA before they can be marketed and distributed within the country. (serviciolegal.com.co)

Importers in Colombia must adhere to specific licensing requirements to legally bring pharmaceutical products into the country. This includes obtaining a Tax Identification Number (NIT) and registering with the Single Tax Registry (RUT) through the National Tax and Customs Directorate (DIAN). Additionally, importers are required to register with the Single Window for Foreign Trade (VUCE) platform. For health-related products, prior approval from INVIMA is mandatory, and importers must secure permits from relevant government agencies before the cargo departs from the country of origin.

Imported pharmaceutical products must undergo batch testing to ensure they meet Colombian quality standards. Stability requirements are enforced to guarantee the products' efficacy and safety throughout their shelf life. Labeling must be in Spanish and include all necessary information as stipulated by INVIMA, such as dosage instructions, active ingredients, and storage conditions. Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the market. These regulations are designed to protect public health and maintain the integrity of the pharmaceutical supply chain in Colombia.

Between 2024 and 2026, Colombia implemented significant updates to its customs and import regulations. Decree 659 of 2024 introduced new mandatory procedures for almost all import shipments, including the requirement for an Advanced Import Declaration to be submitted at least 48 hours prior to the arrival of cargo in Colombia. These changes aim to enhance customs controls and streamline the import process. Importers must stay informed about these regulatory updates to ensure compliance and avoid potential disruptions in their supply chains.

Cipla Colombia SAS Y/O Deposito UPS's product strategy focuses on importing pharmaceutical formulations across three therapeutic categories: Respiratory (79.6%), Antivirals (14.3%), and Advanced Oncology (6.1%). This strategic focus aligns with the significant demand for respiratory medications, particularly in the context of chronic respiratory diseases prevalent in Colombia. The inclusion of antiviral and oncology products addresses critical healthcare needs, reflecting the company's commitment to providing comprehensive therapeutic solutions. The substantial import value of Salbutamol, a key respiratory medication, underscores the market's demand for such treatments.

Cipla Colombia SAS Y/O Deposito UPS's sourcing strategy is heavily centered on generic drug formulations, with a particular emphasis on respiratory medications. The exclusive partnership with Cipla Limited, an Indian multinational pharmaceutical company, facilitates access to a diverse range of high-quality generic products. This collaboration enables the company to offer cost-effective therapeutic options to the Colombian market, catering to the needs of both public and private healthcare sectors.

Based on its product mix, Cipla Colombia SAS Y/O Deposito UPS primarily serves the wholesale distribution segment of the Colombian pharmaceutical market. By importing and distributing a wide array of pharmaceutical formulations, the company ensures that various healthcare providers, including hospitals, clinics, and pharmacies, have access to essential medications. This positioning allows Cipla Colombia SAS Y/O Deposito UPS to play a pivotal role in maintaining the supply chain of critical therapeutic products across Colombia.

There is a realistic opportunity for new Indian suppliers to collaborate with Cipla Colombia SAS Y/O Deposito UPS. The company's exclusive sourcing from Cipla Limited indicates a potential openness to diversifying its supplier base. Indian exporters can explore this opportunity by offering complementary products, ensuring competitive pricing, and demonstrating reliability in supply chain operations. Additionally, understanding the regulatory requirements and quality standards specific to the Colombian market will be crucial for establishing successful partnerships.

Indian exporters aiming to supply Cipla Colombia SAS Y/O Deposito UPS and the broader Colombian market must ensure compliance with INVIMA's regulatory standards. This includes obtaining sanitary registration for pharmaceutical products, adhering to Good Manufacturing Practice (GMP) certifications recognized by INVIMA, and ensuring that products meet Colombian labeling and packaging requirements. Additionally, exporters must navigate Colombia's import licensing procedures, including registration with DIAN and the VUCE platform, to facilitate smooth market entry.

To establish a partnership with Cipla Colombia SAS Y/O Deposito UPS, Indian exporters should initiate contact through formal channels, presenting their product portfolios and demonstrating compliance with Colombian regulatory standards. Participating in relevant trade fairs and industry events in Colombia can also provide opportunities to connect with the company. Understanding the import licensing requirements and ensuring timely submission of necessary documentation will be essential for a successful collaboration. Building a relationship based on trust, reliability, and mutual benefit will be key to entering the Colombian pharmaceutical market.